Kody Technolab Limited has entered into a tripartite agreement with Falcon Tech Robotics LLC and Sscore AI Tech Diagnostic Limited, appointing it as the exclusive worldwide manufacturer of its Medigo range of AI-powered healthcare screening robots. The three-year agreement, effective from June 22, 2026, establishes a commercial framework for the manufacture, supply, distribution, and deployment of these robotic solutions across global markets, targeting a significant unmet need in the healthcare sector.

Agreement Structure and Market Context

Under the agreement, Kody Technolab will manufacture the products on an exclusive worldwide basis, while Falcon Tech Robotics, the company's UAE-based joint venture, will serve as the exclusive global distributor. Sscore AI Tech Diagnostic Limited is responsible for the worldwide deployment and commercialization of the products. Manufacturing and supply of Medigo units are scheduled to commence in H1 of FY 2026-27, supported by a binding minimum purchase framework structured across biannual commercial periods.

The agreement targets the global preventive healthcare market, which industry research projects to grow from approximately USD 268.7 billion in 2023 to USD 585.6 billion by 2030. This expansion addresses the gap where an estimated 4.5 billion people lack full access to essential health services, according to the WHO and World Bank.

The Medigo Product Range

The Medigo range comprises four AI-powered healthcare screening robots designed for clinical-grade preventive screening without dependence on specialized medical staff.

Each unit screens for conditions across metabolic, cardiovascular, infectious, sensory, and mental health categories, generating consolidated reports in the patient’s preferred language and feeding real-time anonymised data into health dashboards.

Strategic Terms and Management Commentary

The agreement includes provisions relating to exclusivity, software support, confidentiality, warranties, intellectual property, and indemnities. It specifies that if Sscore fails to meet minimum purchase commitments, the exclusive manufacturing and supply obligations of Kody and Falcon shall automatically cease, allowing them to engage with third parties. Kody retains the right to continue the agreement on a non-exclusive basis or terminate it upon a 15-day written notice.

Manav Subhashchandra Patel, Managing Director of Kody Technolab Limited, stated that the agreement is a defining moment in the company's journey to scale its healthcare robotics platform globally. Prashant Sawant, Chairman & MD of Sscore AI Tech Diagnostic Limited, highlighted that the Medigo platform offers a uniquely scalable solution to meet critical unmet needs in preventive screening.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0Q7P01013/ae8100cb241042eb.pdf

kody technolab has secured trading approval from the National Stock Exchange of India (NSE) for 13,88,000 fully paid-up equity shares. The allotment follows the conversion of 6,94,000 warrants on a preferential basis and the issuance of 6,94,000 bonus equity shares. The company communicated this development in a regulatory filing dated May 22, 2026.

Listing Details

The NSE has confirmed that the equity shares of the company are listed and admitted to dealings effective May 25, 2026. The securities are classified under the 'SM' series with the symbol 'KODYTECH'. The shares have a face value of Rs. 10/- each.

Lock-in Period

A portion of the newly issued shares is subject to a lock-in period as per regulatory requirements. The lock-in schedule varies for different tranches of the shares, with expiry dates extending into late 2027.

The company has ensured compliance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the disclosure of this information.